NMN Supplementation During Pregnancy Reduces Birth Defects in Animal Study

Intrauterine growth restriction (IUGR) affects up to 10% of pregnancies and can lead to serious complications for both mother and baby. Poor placental function, often linked to mitochondrial dysfunction, is a major contributing factor to IUGR.

Researchers investigated whether maternal supplementation with β-Nicotinamide Mononucleotide (NMN), a precursor to NAD+ that supports cellular energy production, could improve pregnancy outcomes in pigs. NMN has gained attention for its potential anti-aging properties and ability to enhance mitochondrial function.

The study found that maternal NMN supplementation significantly reduced IUGR rates compared to control groups. The beneficial effects appeared to work through improved mitochondrial function in the placenta, specifically via activation of the AMPK/PGC-1α pathway. This pathway is critical for mitochondrial biogenesis and energy metabolism.

These findings could have important implications for human pregnancy health, as placental mitochondrial dysfunction is also linked to pregnancy complications in humans. If similar effects occur in human pregnancies, NMN supplementation might offer a novel approach to preventing IUGR and improving birth outcomes.

However, this research was conducted in pigs, and human studies would be needed to confirm safety and efficacy. The optimal dosing, timing, and long-term effects of maternal NMN supplementation remain unknown and require further investigation before clinical applications.